DFDS A/S
25.2.2021 17:12:37 CET | Globenewswire | Press release
| Company announcement no. 11/2021 |
In compliance with Article 19 of EU Regulation no. 596/2014, transactions are reported related to shares in DFDS A/S made by executives in DFDS and/or persons closely associated with them.
The transactions of Torben Carlsen, CEO, are reported in the table below.
| Name | Torben Carlsen |
| Position | CEO |
| Issuer | DFDS |
| ID code | DK 0060655629 |
| Initial notification/ Amendment | Initial notification |
| Instrument | Shares |
| Transactions |
|
| Transaction date | 23-24 February 2021 |
| Price and volume |
|
| Transaction values |
|
| Market | XCSE, Nasdaq Copenhagen |
The Executive Board’s holding of shares in DFDS is available from this link
Contact
Torben Carlsen, CEO, +45 33 42 32 01
Karina Deacon, CFO, +45 33 42 33 42
Søren Brøndholt Nielsen, IR, +45 33 42 33 59
Nicole Seroff, Communications, +45 31 40 34 46
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
Orion Oyj18.9.2026 18:00:00 CEST | Press release
Orion Corporation: Acquisition of own shares during week 38, 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
